Altimmune 2025: Redefining Obesity And MASH Treatment

Company Overview - Altimmune is a small-cap biotech company focused on developing a GLP-1/Glucagon dual-agonist peptide called Pemvidutide [1] - The company has pivoted multiple times in its history but is now targeting the obesity and MASH (metabolic dysfunction-associated steatohepatitis) markets [1] Product Focus - Pemvidutide is a key product in the company's pipeline, aimed at addressing obesity and MASH [1] Market Strategy - The company is positioning itself in the growing markets of obesity and MASH, which are significant areas of unmet medical need [1]